Institutional ticker directory tracking stock mentions, long/short ideas, and high-conviction pitches extracted from quarterly hedge fund letters.
| Ticker | Company | Sector | Industry | Pitches | Stance |
|---|---|---|---|---|---|
| Fund / Manager | Thesis Excerpt | Stance | Period / Date | Action |
|---|---|---|---|---|
Artisan Partners Small Cap Fund Jay Warner | “Ascendis Pharma is a biotechnology company leveraging its proprietary TransCon platform to develop differentiated therapies for patients with significant unmet medical needs. Recent results were mixed, with revenue below expectations but EPS meaningfully ahead, supported by R&D leverage and improving operating discipline. Importantly, patient growth for YORVIPATH remained strong, with more than 1,000 new patients added and enrollment momentum continuing despite temporary revenue headwinds from seasonality, free drug programs and European market access. The early launch of YUVIWEL, a treatment for a rare bone-growth disorder, also appears encouraging. SKYTROFA, a long-acting growth hormone therapy for children with growth hormone deficiency, continues to gain share and could benefit from future label expansion. We reduced the position during the quarter after a competitor with an existing treatment for the same rare hormone disorder as YORVIPATH filed a lawsuit against Ascendis. While we do not believe the lawsuit has merit or is likely to affect US sales, we are mindful of the distraction it could create and the potential headwind to the company's profit cycle. We continue to maintain a large position given our conviction in Ascendis' long-term prospects.” | NEUTRAL | Q2 2026 Jul 21, 2026 | View Pitch |
Artisan Global Discovery Jason White | “Ascendis is a biotech company leveraging its proprietary TransCon™ platform to develop differentiated therapies that address unmet medical needs. This technology enables sustained and predictable drug release while preserving the drug's original mechanism of action. The launch of Yorvipath®—the first and only hormone replacement therapy for adult hypoparathyroidism—has exceeded expectations, generating revenues of €103 million in Q2 2025, more than double the prior quarter, with over 3,100 patients and 1,500 US prescribers. This strong uptake reinforces our confidence in both Yorvipath® and Ascendis' broader pipeline. BSD Analysis: The manager highlights durable platform economics with a successful launch validating TransCon. With rapid adoption and expanding prescriber base, revenue visibility improves; pipeline optionality supports multi-year growth. While biotech risk remains, balance sheet and execution de-risk near-term.” | BULL | Q3 2025 Oct 22, 2025 | View Pitch |
Spyglass Capital Management Portfolio Manager | “The manager re-entered Ascendis Pharma following the incredibly successful US commercial launch of Yorvipath for hypoparathyroidism. Yorvipath enjoys monopoly status in hormone replacement therapy after its primary competitor's withdrawal, and is priced at $285,000 annually. Backed by solid clinical endorsement and a massive unmet market, Yorvipath is projected to reach blockbuster status within three to five years.” | BULL | Q3 2025 Sep 30, 2025 | View Pitch |
Each excerpt above is the manager's commentary on this ticker specifically. The full letter has the rest of their portfolio thinking, risk discussion, and broader institutional context.
